GlassScriptPhysician profile
Catherine Mazzella
NPI 1477018935
$3,175.67
in general payments reported to CMS, 2019-2025
34 companies · $566 in 2025
The $566 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $961 · 2022: $532 · 2023: $769 · 2024: $347 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,396 · Education: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.21 |
| Education | $285.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $458.91 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $361.40 | 2021-2025 | |
| Janssen Biotech, INC. | $338.37 | 2021-2025 | Talvey, Darzalex, Tecvayli |
| Merck Sharp & Dohme LLC | $191.43 | 2021-2023 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $157.31 | 2021-2025 | Enhertu, Injectafer |
| Astellas Pharma US INC | $149.95 | 2021-2025 | |
| Lilly USA, LLC | $135.42 | 2021-2023 | Retevmo, Jaypirca, Verzenio |
| Genzyme Corporation | $112.67 | 2021-2024 | |
| Pfizer INC. | $98.58 | 2023 | |
| Sanofi-Aventis U.S. LLC | $86.99 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $85.74 | 2021-2025 | |
| Seagen INC. | $79.91 | 2021-2022 | |
| Dova Pharmaceuticals | $77.39 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.38 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $69.49 | 2024-2025 | Ultomiris |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $69.19 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $68.04 | 2021-2023 | Libtayo |
| Jazz Pharmaceuticals INC. | $66.76 | 2021-2022 | |
| Coherus Oncology, INC. | $60.70 | 2024 | |
| Puma Biotechnology, INC. | $53.90 | 2022-2023 | |
| Taiho Oncology, INC. | $52.40 | 2022-2023 | |
| Abiomed | $38.52 | 2025 | |
| Sobi, INC | $32.95 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $30.66 | 2021 | |
| Morphosys, US INC. | $30.29 | 2021 | |
| Myovant Sciences INC. | $28.48 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.04 | 2022 | |
| Genentech USA, INC. | $22.96 | 2025 | Phesgo |
| Pharmacyclics LLC, An Abbvie Company | $22.48 | 2021 | |
| Array Biopharma INC | $22.23 | 2023 | Lorbrena, Braftovi, Comirnaty |
| Cti Biopharma Corp. | $21.95 | 2023 | Vonjo |
| Baxter Healthcare | $19.27 | 2025 | Fluid Systems - Premix Drugs |
| Janssen Pharmaceuticals, INC | $18.79 | 2021 | |
| Epizyme, INC. | $17.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Mazzella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.